At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 15 enrolled
Drug / intervention
guselkumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label Pilot Trial of Guselkumab in the Treatment of Adults With Pityriasis Rubra Pilaris (PRP)
In Brief
A Phase 2 clinical trial evaluating guselkumab for Pityriasis Rubra Pilaris. Completed, enrolled 15 participants across 1 site.
Detailed Summary
15 patients with PRP will be treated with guselkumab for 20 weeks to determine safety and efficacy. Participants are required to travel to Portland, OR only for the first visit, week-4 visit, and week-24 visit. 3 visits in between these times and one follow up visit may be performed by secure videoconferencing.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPityriasis Rubra Pilaris
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedJun 2019
Enrollment StartOct 2019
Primary CompletionAug 2022
Study CompletionMar 2024
TodayJul 2026
First PostedJun 5, 2019
Enrollment StartOct 3, 2019
Primary CompletionAug 11, 2022
Study CompletionMar 22, 2024
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 7.1 years ago
Interventions
guselkumabbiological
Treatment at the FDA-approved psoriasis dosing for 20 weeks